225 related articles for article (PubMed ID: 38374435)
1. Tabelecleucel is effective in EBV-positive lymphoproliferative disease.
Romero D
Nat Rev Clin Oncol; 2024 Apr; 21(4):251. PubMed ID: 38374435
[No Abstract] [Full Text] [Related]
2. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
Mahadeo KM; Baiocchi R; Beitinjaneh A; Chaganti S; Choquet S; Dierickx D; Dinavahi R; Duan X; Gamelin L; Ghobadi A; Guzman-Becerra N; Joshi M; Mehta A; Navarro WH; Nikiforow S; O'Reilly RJ; Reshef R; Ruiz F; Spindler T; Prockop S
Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
[TBL] [Abstract][Full Text] [Related]
3. Tabelecleucel: First Approval.
Keam SJ
Mol Diagn Ther; 2023 May; 27(3):425-431. PubMed ID: 37016096
[TBL] [Abstract][Full Text] [Related]
4. [The cutting-edge of medicine; Epstein-Barr virus associated lymphoproliferative disorders: disease concept and treatment].
Suzuki R
Nihon Naika Gakkai Zasshi; 2013 Apr; 102(4):979-85. PubMed ID: 23772516
[No Abstract] [Full Text] [Related]
5. Systemic Epstein-Barr Virus-positive T-Cell Lymphoproliferative Disease of Childhood With Good Response to Steroid Therapy.
Kim DH; Kim M; Kim Y; Han K; Han E; Lee JW; Chung NG; Cho B
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e497-e500. PubMed ID: 28697169
[TBL] [Abstract][Full Text] [Related]
6. Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications.
Subramaniam K; Cherian M; Jain S; Latimer M; Corbett M; D'Rozario J; Pavli P
Intern Med J; 2013 Dec; 43(12):1339-42. PubMed ID: 24330365
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-associated hydroa vacciniforme-like lymphoproliferative syndrome: excellent response to antiviral therapy.
İmren IG; Demirkan N; Çomut E; Duygulu Ş
Int J Dermatol; 2020 Dec; 59(12):e452-e454. PubMed ID: 32808321
[No Abstract] [Full Text] [Related]
8. Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa.
Mwanda WO; Whalen C; Remick SC
East Afr Med J; 2005 Sep; 82(9 Suppl):S133-4. PubMed ID: 16619688
[No Abstract] [Full Text] [Related]
9. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
[TBL] [Abstract][Full Text] [Related]
11. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
12. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
[TBL] [Abstract][Full Text] [Related]
14. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV
Chaganti S; Barlev A; Caillard S; Choquet S; Cwynarski K; Friedetzky A; González-Barca E; Sadetsky N; Schneeberger S; Thirumalai D; Zinzani PL; Trappe RU
Adv Ther; 2023 Mar; 40(3):1267-1281. PubMed ID: 36681739
[TBL] [Abstract][Full Text] [Related]
15. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
Transpl Infect Dis; 2019 Aug; 21(4):e13116. PubMed ID: 31102475
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus reactivation influences clonal evolution in human herpesvirus-8-related lymphoproliferative disorders.
Granai M; Facchetti M; Mancini V; Goedhals J; Sherriff A; Mundo L; Bellan C; Amato T; Sorrentino E; Ungari M; Raphael M; Leoncini L; Facchetti F; Lazzi S
Histopathology; 2021 Dec; 79(6):1099-1107. PubMed ID: 34431125
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies for posttransplant lymphoproliferative disorder.
Perkins JD
Liver Transpl; 2006 Jun; 12(6):1013-4. PubMed ID: 16823952
[No Abstract] [Full Text] [Related]
18. EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.
Toner K; Bollard CM
Blood; 2022 Feb; 139(7):983-994. PubMed ID: 34437680
[TBL] [Abstract][Full Text] [Related]
19. Fulminant Epstein-Barr virus-driven CD8 positive T-cell lymphoproliferative disorder with chromosomal abnormality.
Tanoshima R; Goto H; Kato H; Yokosuka T; Kajiwara R; Yokota S
Pediatr Blood Cancer; 2011 Jul; 57(1):182. PubMed ID: 21445947
[No Abstract] [Full Text] [Related]
20. Aggressive Tongue Root Epstein-Barr Virus-Positive Mucocutaneous Ulcer Treated With Rituximab Alone.
Tsutsumi M; Yoshimura T; Tatsumi N; Nakaya Y; Fuseya H; Horiuchi M; Yoshida M; Hayashi Y; Nakao T; Inoue T; Yamane T
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):e291-e294. PubMed ID: 32179033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
